

## Literatura ACTA MEDICINAE 1–2/2022 Diabetologie | Kardiologie

- 2 **Nová antidiabetika na dohled**  
prof. MUDr. Milan Kvapil, CSc. Geriatrická interní klinika 2. LF UK a FN v Motole, Česká diabetologická společnost ČLS JEP, Praha
- 2 **Praktické rady pro použití poslední generace inzulinových pump**  
MUDr. Michal Krčma, Ph.D. Diabetologické centrum, 1. interní klinika FN Plzeň, Univerzita Karlova, Lékařská fakulta v Plzni
- 2 **Nikotin a diabetes mellitus**  
prof. MUDr. Jan Škrha, DrSc., MBA III. interní klinika 1. LF UK a Všeobecné fakultní nemocnice, Praha
- 2 **Komu prospěje léčba IDegAsp?**  
doc. MUDr. Alena Šmahelová, Ph.D. III. interní gerontometabolická klinika FN a LF UK, Hradec Králové
- 3 **Přínos dulaglutidu pro snížení kardiovaskulárního rizika**  
MUDr. Barbora Doležalová Univerzita Pardubice, Fakulta zdravotnických studií, Pardubice
- 3 **Semaglutid: SUSTAIN, PIONEER**  
MUDr. Tomáš Edelsberger Diabetologická ordinace pro dospělé, Krnov
- 3 **Jak dosáhnout s inzulinem Toujeo ve spojení s flash glucose monitoring lepší kontroly diabetu 1. typu – kazuistika**  
MUDr. Marie Löblová Diaclinic, s. r. o., České Budějovice
- 4 **Přínos terapie gliptiny u seniorních diabetiků**  
MUDr. Jindřich Olšovský, Ph.D. II. interní klinika, Diabetologická ambulance FN u sv. Anny v Brně | MUDr. Lucie Břízová | prof. MUDr. Milan Kvapil, CSc., MBA | MUDr. Martina Nováková Geriatrická interní klinika 2. LF UK a FN v Motole, Praha
- 4 **Biologická krytí v léčbě syndromu diabetické nohy**  
MUDr. Vladimíra Fejfarová, Ph.D. Diabetologické centrum, IKEM a 2. LF UK, Praha  
MUDr. Veronika Wosková | MUDr. Michal Dubský Diabetologické centrum, IKEM, Praha  
MUDr. Karol Sutoris, Ph.D. Klinika transplantáční chirurgie, transplantcentrum, IKEM, Praha
- 4 **Využití moderních materiálů v lokální léčbě syndromu diabetické nohy – kazuistiky**  
MUDr. Robert Bém, Ph.D., MHA Centrum diabetologie, Institut klinické a experimentální medicíny, Praha
- 4 **Co přináší nová doporučení pro léčbu srdečního selhání 2021 pro kardiology v první linii a praktické lékaře**  
prof. MUDr. Jiří Vítovec, CSc., FESC | prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC  
I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně
- 5 **Souhrn novinek z Doporučení pro diagnostiku a léčbu srdečního selhání Evropské kardiologické společnosti z roku 2021**  
prof. MUDr. Filip Málek, Ph.D., MBA Kardiovaskulární centrum Nemocnice Na Homolce, Praha
- 5 **Novinky v léčbě akutního srdečního selhání**  
prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC  
I. interní kardiologická klinika FN u sv. Anny v Brně a LF MU, Brno
- 5 **Vericiguat v léčbě srdečního selhání**  
prof. MUDr. Vojtěch Melenovský, CSc. Klinika kardiologie, Institut klinické a experimentální medicíny, Praha
- 5 **Postavení spironolaktonu v terapii srdečního selhání**  
prof. MUDr. Filip Málek, Ph.D., MBA Kardiovaskulární centrum Nemocnice Na Homolce, Praha
- 5 **SGLT2 a kardiovaskulární onemocnění v roce 2022**  
prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC  
I. interní kardiologická klinika FN u sv. Anny v Brně a LF MU, Brno
- 6 **Klinické zkušenosti s moxonidinem v léčbě arteriální hypertenze – kazuistiky**  
MUDr. Jan Vachek Klinika nefrologie 1. LF UK a VFN, Praha, Interní oddělení a hemodialyzační středisko Klatovské nemocnice, a. s.
- 6 **Měření krevního tlaku u pacientů s arytmiemi – v ambulanci i doma**  
MUDr. Petra Vysočanová Interní kardiologická klinika FN a LF MU, Brno
- 6 **Fibrilace síní – možnost řešení na jednotce intenzivní péče – kazuistika**  
Oleksii Stoiano | Eliška Klepšová anesteziologové, IKEM, Praha
- 6 **Adherence pacientů s chronickým žilním onemocněním k doporučené léčbě**  
MUDr. Eva Jirešová Angiologická ambulance, Kardiocentrum Nemocnice Na Homolce, Praha

# Nová antidiabetika na dohled

prof. MUDr. Milan Kvapil, CSc. Geriatrická interní klinika 2. LF UK a FN v Motole, Česká diabetologická společnost ČLS JEP, Praha

- 1 Dostupné z: <https://www.sukl.cz/klinicke-hodnoceni-leku>, vyhledáno 1. 3. 2022.
- 2 Dostupné z: [https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/investor\\_presentations/2020/20201030\\_Q3%202020-conference-call-presentation.pdf](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/investor_presentations/2020/20201030_Q3%202020-conference-call-presentation.pdf), vyhledáno 1. 3. 2022.
- 3 Dostupné z: <https://www.novonordisk.com/science-and-technology/r-d-pipeline.html>, vyhledáno 1. 3. 2022.
- 4 Dostupné z: <https://professional.diabetes.org/abstract/interim-results-phase-iii-clinical-trial-dna-plasmid-vaccine-bht-3021-type-1-diabetes>, vyhledáno 1. 3. 2022.
- 5 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT04279613?term=plasmid+encoding+pre+and+pro-insulin&cond=Diabetes+Type+1&draw=2&rank=1>, vyhledáno 1. 3. 2022.
- 6 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT04575181>, vyhledáno 1. 3. 2022.
- 7 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT04259801>, vyhledáno 1. 3. 2022.
- 8 Dostupné z: <https://www.globenewswire.com/news-release/2020/06/18/2050266/0/en/Novo-Nordisk-successfully-completes-AM833-phase-2-trial-and-phase-1-combination-trial-with-AM833-and-semaglutide-in-obesity.html>, vyhledáno 1. 3. 2022.
- 9 Rosenstock, J. – Bajaj, H. S. – Janež, A., et al.; NN1436-4383 Investigators. Once-weekly insulin for type 2 diabetes without previous insulin treatment. *N Engl J Med*, 2020, 383, s. 2107–2116.
- 10 Bajaj, H. S. – Bergenstal, R. M. – Christoffersen, A., et al.: Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. *Diabetes Care*, 2021, 44, s. 1586–1594.
- 11 Lingvay, I. – Buse, J. B. – Franek, E., et al.: A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100. *Diabetes Care*, 2021, 44, s. 1595–1603.
- 12 DiMarchi, R. D. – Mayer, J. P.: Icodec advances the prospect of once-weekly insulin injection. *J Med Chem*, 2021, 64, s. 8939–8941.
- 13 Kjeldsen, T. B. – Hubálek, F. – Hjørringgaard, C. U., et al.: Molecular engineering of insulin icodec, a first acylated insulin analog for once-weekly administration in humans. *J Med Chem*, 2021, 64, s. 8942–8950.
- 14 Nishimura, E. – Pridal, L. – Glendorf, T., et al.: Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. *BMJ Open Diabetes Research and Care*, 2021, 9, s. e002301.
- 15 Griffin, T. P. – Dinneen, S. F.: In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA<sub>1c</sub> or significant/severe hypoglycemia. *Ann Intern Med*, 2021, 174, s. JC34.
- 16 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT05013229>, vyhledáno 1. 3. 2022.
- 17 Frias, J. P. – Auerbach, P. – Bajaj, H. S., et al.: Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. *Lancet Diabetes Endocrinol*, 2021, 9, s. 563–574.

# Praktické rady pro použití poslední generace inzulinových pump

MUDr. Michal Krčma, Ph.D. Diabetologické centrum, 1. interní klinika FN Plzeň, Univerzita Karlova, Lékařská fakulta v Plzni

- 1 Braune, K. – Lal, R. A. – Petruželková, L., et al.; OPEN International Healthcare Professional Network and OPEN Legal Advisory Group: Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. *Lancet Diabetes Endocrinol*, 2022, 10, s. 58–74.
- 2 Da Silva, J. – Lepore, G. – Battelino, T., et al.: Real-world performance of the MiniMed 780G system: first report of outcomes from 4120 users. *Diabetes Technol Ther*, 2022, 24, s. 113–119.
- 3 Ekhlaspour, L. – Schoelwer, M. J. – Forlenza, G. P., et al.: Safety and performance of the tandem t:slim X2 with Control-IQ automated insulin delivery system in toddlers and preschoolers. *Diabetes Technol Ther*, 2021, 23, s. 384–391.
- 4 Isganaitis, E. – Raghinaru, D. – Ambler-Osborn, L., et al.; iDCL Trial Research Group: Closed-loop insulin therapy improves glycemic control in adolescents and young adults: outcomes from the international diabetes closed-loop trial. *Diabetes Technol Ther*, 2021, 23, s. 342–349.
- 5 Leelarathna, L. – Choudhary, P. – Wilmot, E. G., et al.: Hybrid closed-loop therapy: Where are we in 2021? *Diabetes Obes Metab*, 2021, 23, s. 655–660.
- 6 McVean, J. – Miller, J.: MiniMed 780G insulin pump system with smartphone connectivity for the treatment of type 1 diabetes: overview of its safety and efficacy. *Expert Rev Med Devices*, 2021, 18, s. 499–504.
- 7 REPOSE Study Group: Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). *BMJ*, 2017, 356, s. j1285.
- 8 Soupal, J. – Petruželková, L. – Grunberger, G., et al.: Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study. *Diabetes Care*, 2020, 43, s. 37–43.
- 9 Teo, E. – Hassan, N. – Tam, W., et al.: Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. *Diabetologia*, 2022, dostupné z: <https://doi.org/10.1007/s00125-021-05648-4>, vyhledáno 15. 2. 2022.

# Nikotin a diabetes mellitus

prof. MUDr. Jan Škrha, DrSc., MBA III. interní klinika 1. LF UK a Všeobecné fakultní nemocnice, Praha

- 1 Yuan, S. – Larsson, S. C.: A causal relationship between cigarette smoking and type 2 diabetes mellitus: A Mendelian randomization study. *Sci Rep*, 2019, 9, s. 19342.
- 2 Willi, C., et al.: Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA*, 2007, 298, s. 2654–2664.
- 3 Al-Delaimy, W. K., et al.: Smoking and mortality among women with type 2 diabetes The Nurses' Health Study cohort. *Diabetes Care*, 2001, 24, s. 2043–2048.
- 4 Yoshikawa, H., et al.: Evidence for functional nicotinic receptors on pancreatic β cells. *Metabolism*, 2005, 54, s. 247–254.
- 5 Xu, H. – Wang, Q. – Sun, Q., et al.: In type 2 diabetes induced by cigarette smoking, activation of p38MAPK is involved in pancreatic β-cell apoptosis. *Environ Sci Pollut Res Int*, 2018, 25, s. 9817–9827.
- 6 Sun, L. – Wang, X. – Gu, T., et al.: Nicotine triggers islet β cell senescence to facilitate the progression of type 2 diabetes. *Toxicology*, 2020, 441, s. 152502.
- 7 Pietrobon, C. B. – Lisboa, P. C. – Bertasso, I. M., et al.: Pancreatic steatosis in adult rats induced by nicotine exposure during breastfeeding. *Endocrine*, 2021, 72, s. 104–115.
- 8 Morimoto, A. – Tatsumi, Y. – Deura, K., et al.: Impact of cigarette smoking on impaired insulin secretion and insulin resistance in Japanese men: The Saku Study. *J Diabetes Investig*, 2013, 4, s. 274–280.
- 9 Oba, S. – Suzuki, E. – Yamamoto, M., et al.: Active and passive exposure to tobacco smoke in relation to insulin sensitivity and pancreatic β-cell function in Japanese subjects. *Diabetes Metab*, 2015, 41, s. 160–167.
- 10 Artese, A. – Stamford, B. A. – Moffatt, R. J.: Cigarette smoking: an accessory to the development of insulin resistance. *Am J Lifestyle Med*, 2019, 13, s. 602–605.
- 11 Li, M. – Li, Ch. – Liu, Y., et al.: Decreased secretion of adiponectin through its intracellular accumulation in adipose tissue during tobacco smoke exposure. *Nutr Metab*, 2015, 12, s. 15.
- 12 Li, Z., et al.: Nicotine induces insulin resistance via down regulation of Nrf2 in cardiomyocyte. *Mol Cell Endocrinol*, 2019, 495, s. 110507.
- 13 Rehman, K. – Haider, K. – Akash, M. S. H.: Cigarette smoking and nicotine exposure contributes for aberrant insulin signaling and cardiometabolic disorders. *Eur J Pharmacol*, 2021, 909, s. 174410.
- 14 Somm, E., et al.: Prenatal nicotine exposure alters early pancreatic islet and adipose tissue development with consequences on the control of body weight and glucose metabolism later in life. *Endocrinology*, 2008, 149, s. 6289–6299.
- 15 Bruin, J. E. – Petre, M. A. – Raha, S., et al.: Fetal and neonatal nicotine exposure in wistar rats causes progressive pancreatic mitochondrial damage and beta cell dysfunction. *PLoS One*, 2008, 3, s. e3371.
- 16 Bhattacharjee, A. – Prasad S. K. – Banerjee, O., et al.: Targeting mitochondria with folic acid and vitamin B12 ameliorates nicotine mediated islet cell dysfunction. *Environ Toxicol*, 2018, 33, s. 988–1000.
- 17 Valdivielso, P. – Hidalgo, A. – Rioja, J., et al.: Smoking and postprandial triglycerides are associated with vascular disease in patients with type 2 diabetes. *Atherosclerosis*, 2007, 194, s. 391–396.
- 18 Huang, K. – Ma, Y. – Wang, J., et al.: The correlation between transcutaneous oxygen tension and microvascular complications in type 2 diabetic patients. *J Diabetes Complications*, 2017, 31, s. 886–890.
- 19 Abdelghany, T. M. – Ismail, R. – Mansoor, F. A., et al.: Cigarette smoke constituents cause endothelial nitric oxide synthase dysfunction and uncoupling due to depletion of tetrahydrobiopterin with degradation of GTP cyclohydrolase. *Nitric Oxide*, 2018, 76, s. 113–121.
- 20 Xia, N., et al.: Review of the role of cigarette smoking in diabetic foot. *J Diabetes Investig*, 2019, 10, s. 202–215.
- 21 Wei, Y. – Lai, B. – Liu, H., et al.: Effect of cigarette smoke extract and nicotine on the expression of thrombospondin and endothelial protein C receptor in cultured human umbilical vein endothelial cells. *Mole Med Rep*, 2018, 17, s. 1724–1730.

# Komu prospěje léčba IDegAsp?

doc. MUDr. Alena Šmahelová, Ph.D. III. interní gerontometabolická klinika FN a LF UK, Hradec Králové

- 1 Giugliano, D. – Maiorino, M. I. – Bellastella, G., et al.: Efficacy of insulin analogs in achieving the hemoglobin A1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials. *Diab Care*, 2011, 34, s. 510–517.
- 2 Peyrot, M. – Barnett, A. H. – Meneghini, L. F., et al.: Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. *Diabet Med*, 2012, 29, s. 682–689.
- 3 Marrett, E. – Stargardt, T. – Mavros, P., et al.: Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. *Diabetes Obes Metab*, 2009, 11, s. 1138–1144.
- 4 Cengiz, E. – Swan, K. L. – Tamborlane, W. V., et al.: The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. *Diabetes Care*, 2012, 35, s. 690–692.
- 5 Jehle, P. M. – Micheler, C. – Jehle, D. R., et al.: Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. *Lancet*, 1999, 354, s. 1604–1607.
- 6 Dardano, A. – Penno, G. – DelPrato, S., et al.: Optimal therapy of type 2 diabetes: a controversial challenge. *Aging*, 2014, 6, s. 187–207.
- 7 Jonassen, I. – Havelund, S. – Hoeg-Jensen, T., et al.: Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. *Pharm Res*, 2012, 29, s. 2104–2114.
- 8 Ryzodeg – Souhrn údajů o přípravku, 2021.
- 9 Fulcher, G. R. – Christiansen, J. S. – Bantwal, G., et al.: Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. *Diabetes Care*, 2014, 37, s. 2084–2090.
- 10 Marso, S. P. – McGuire, D. K. – Zimman, B., et al.: Efficacy and safety of degludec versus glargine in type 2 diabetes. *N Engl J Med*, 2017, 377, s. 723–732.

# Přínos dulaglutidu pro snížení kardiovaskulárního rizika

MUDr. Barbora Doležalová Univerzita Pardubice, Fakulta zdravotnických studií, Pardubice

- 1 American Diabetes Association Professional Practice Committee: **Draznin, B. – Aroda, V. R. – Bakris, G., et al.**: 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2022. *Diabetes Care*, 2022, 45, suppl. 1, s. S144–S174.
- 2 International Diabetes Federation (IDF) (2019). *Diabetes atlas*. Dostupné z: <https://diabetesatlas.org/en/resources/>, vyhledáno 25. 2. 2022.
- 3 **Anderson, J. E. – Thieu, V. T. – Boyle, K. S., et al.**: Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. *Postgrad Med*, 2016, 128, s. 810–821.
- 4 **Dungan, K. M., et al.**: Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. *Lancet*, 2014, 384, s. 1349–1357.
- 5 **Robinson, S., et al.**: Real-world effectiveness of dulaglutide in patients with type 2 diabetes mellitus: a literature review. *Diabetes Ther*, 2020, 11, s. 1437–1466.
- 6 **Mody, R. – Huang, Q. – Yu, M., et al.**: Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study. *BMJ Open Diab Res Care*, 2019, 7, s. e000884.
- 7 **Gerstein, H. C. – Colhoun, H. M. – Dagenais, G. R., et al.**: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*, 2019, 394, s. 121–130.
- 8 **Gerstein, H. C. – Colhoun, H. M. – Dagenais, G. R., et al.**: Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. *Lancet*, 2019, 394, s. 131–138.
- 9 Authors/Task Force Members; **Rydén, L. – Grant, P. J. – Anker, S. D., et al.**: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J*, 2013, 34, s. 3035–3087.
- 10 **Ferranini, G. – Gerstein, H. – Colhoun, H. M., et al.**: Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. *Eur Heart J*, 2021, 42, s. 2565–2573.
- 11 **Buse, J. – Wexler, D. J. – Tsapas, A., et al.**: 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 2020, 43, s. 487–493.
- 12 American Diabetes Association Professional Practice Committee; **Draznin, B. – Aroda, V. R. – Bakris, G., et al.**: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes 2022. *Diabetes Care*, 2022, 45, suppl. 1, s. S125–S143.
- 13 **Konig, M. – Riddle, M. C. – Colhoun, H. M., et al.**: Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. *Cardiovasc Diabetol*, 2021, 20, s. 194.

## Semaglutid: SUSTAIN, PIONEER

MUDr. Tomáš Edelsberger Diabetologická ordinace pro dospělé, Krnov

- 1 **Lau, J. et al.**: Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. *J Med Chem*, 2015, 58, s. 7370–7380.
- 2 **Nauck, M. A.**: A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 Analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. *Diabetes Care*, 2016, 39, s. 231–241.
- 3 Dostupné z: [https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf), vyhledáno 3. 3. 2022.
- 4 **Sorli, C., et al.**: Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. *Lancet Diabetes Endocrinol*, 2017, 5, s. 251–260.
- 5 **Ahrén, B., et al.**: Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. *Lancet Diabetes Endocrinol*, 2017, 5, s. 341–354.
- 6 **Ahmann, A. J., et al.**: Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. *Diabetes Care*, 2018, 41, s. 258–266.
- 7 **Aroda, V. R., et al.**: Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. *Lancet Diabetes Endocrinol*, 2017, 5, s. 355–366.
- 8 **Rodbard, H. W., et al.**: Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. *J Clin Endocrinol Metab*, 2018, 103, s. 2291–2301.
- 9 **Marso, S. P., et al.**: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*, 2016, 375, s. 1834–1844.
- 10 **Pratley, R. E. et al.**: Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *Lancet Diabetes Endocrinol*, 2018, 6, s. 275–286.
- 11 **Bain, S. C., et al.**: Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. *Diabetes Obes Metab*, 2019, 21, s. 499–508.
- 12 **Davies, M., et al.**: Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. *JAMA*, 2017, 318, s. 1460–1470.
- 13 **Goldenberg, R. M., et al.**: Semaglutide: review and place in therapy for adults with type 2 diabetes. *Can J Diabetes*, 2019, 43, s. 136–145.
- 14 **Kvapil, M.**: Kardiovaskulární bezpečnost liraglutidu a semaglutidu. *Remedia*, 2016, s. 416–418.
- 15 **Edelsberger, T.**: Kardiovaskulární bezpečnost antidiabetik v roce 2018. *Remedia*, 2018, s. 5.
- 16 **Ahrén, B., et al.**: Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. *Diabetes Obes Metab*, 2018, 20, s. 2210–2219.
- 17 **O'Neil, P. M. – Birkenfeld, A. L. – McGowan, B., et al.**: Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. *Lancet*, 2018, 392, s. 637–649.
- 18 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03548935>, vyhledáno 3. 3. 2022.
- 19 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03552757>, vyhledáno 3. 3. 2022.
- 20 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03611582>, vyhledáno 3. 3. 2022.
- 21 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03548987>, vyhledáno 3. 3. 2022.
- 22 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03574597>, vyhledáno 3. 3. 2022.
- 23 Dostupné z: [https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual\\_report/2016/20160208\\_Annual%20Report%202015\\_UK.PDF](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2016/20160208_Annual%20Report%202015_UK.PDF), vyhledáno 3. 3. 2022.
- 24 Dostupné z: <https://www.novomedlink.com/diabetes/products/treatments/ozempic/cost-and-coverage.html>, vyhledáno 3. 3. 2022.
- 25 Dostupné z: <https://www.ajmc.com/view/contributor-how-payers-are-applying-ai-to-solve-the-problem-of-incomplete-data-3-use-cases>, vyhledáno 3. 3. 2022.
- 26 Dostupné z: <https://pharmaintelligence.informa.com/resources/product-content/novos-oral-semaglutide-passes-pioneer-2-but-weight-loss-result-a-bit-disappointing>, vyhledáno 3. 3. 2022.
- 27 **Yabe, D. – Nakamura, J. – Kaneto, H., et al.**: Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. *Lancet Diabetes Endocrinol*, 2020, 8, s. 392–406.
- 28 Dostupné z: <https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=99413>, vyhledáno 3. 3. 2022.
- 29 Dostupné z: <https://nordiclifescience.org/headline-results-from-novo-nordisks-pioneer-8-trial/>, vyhledáno 3. 3. 2022.
- 30 Dostupné z: <https://www.ajmc.com/view/oral-semaglutide-of-fers-superior-a1c-reduction-weight-loss-in-pioneer-5-trial>, vyhledáno 3. 3. 2022.
- 31 **Miles, K. E. – Kerr, J. L.**: Semaglutide for the treatment of type 2 diabetes mellitus. *J Pharm Technol*, 2018, 34, s. 281–289.
- 32 **Lingvay, I. – Catarig, A. M. – Frias, J. P., et al.**: Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. *Lancet Diabetes Endocrinol*, 2019, 7, s. 834–844.
- 33 **Zinman, B., et al.**: Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol*, 2019, 7, s. 356–367.
- 34 **Husain, M., et al.**: PIONEER 6 Investigators: Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*, 2019, 381, s. 841–851.

## Jak dosáhnout s inzulinem Toujeo ve spojení s flash glucose monitoring lepší kontroly diabetu 1. typu – kazuistika

MUDr. Marie Löblová Diaclinic, s. r. o., České Budějovice

- 1 **Škrha, J. – Pelikánová, T. – Prázný, M., et al.**: za ČDS: *Doporučený postup v péči o diabetika 1. typu*. Dostupné z: [https://www.diab.cz/dokumenty/standard\\_DM\\_l.pdf](https://www.diab.cz/dokumenty/standard_DM_l.pdf), vyhledáno 11. 3. 2022.
- 2 **Bergental, R. M. – Bailey, T. S. – Rodbard, D., et al.**: Comparison of insulin glargine 300 units/ml and 100 units/ml in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. *Diabetes Care*, 2017, 40, s. 554–560.
- 3 **Ritzel, R. – Rousset, R. – Giaccari, A., et al.**: Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/ml vs glargine 100 U/ml: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. *Diabetes Obes Metab*, 2018, 20, s. 541–548.

# Přínos terapie gliptiny u seniorních diabetiků

MUDr. Jindřich Olšovský, Ph.D. II. interní klinika, Diabetologická ambulance FN u sv. Anny v Brně

MUDr. Lucie Břízová | prof. MUDr. Milan Kvapil, CSc., MBA | MUDr. Martina Nováková Geriatrická interní klinika 2. LF UK  
a FN v Motole, Praha

- 1 Kvapil, M. – Benešová, K. – Jarkovský, J. – Dušek, L.: Komentář. *Výhledy a výzvy diabetologie*, 2021, 6, s. 187–191.
- 2 Ahrén, B.: Gut peptides and type 2 diabetes mellitus treatment. *Curr Diab Rep*, 2003, 3, s. 365–372.
- 3 Nauck, M. A., et al.: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. *Diabetologia*, 1986, 29, s. 46–52.
- 4 Anagnostis, P. – Athyros, V. G. – Adamidou, F., et al.: Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. *Diabetes Obes Metab*, 2011, 13, s. 302–312.
- 5 De Meester, I., et al.: Natural substrate of dipeptidyl peptidase IV. *Adv Exp Med Biol*, 2000, 477, s. 67–87.
- 6 Amori, R. E., et al.: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. *JAMA*, 2007, 298, s. 194–206.
- 7 Green, J. B.; TECOS Study Group: Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2015, 373, s. 232–242.
- 8 White, W. B.; EXAMINE Investigators: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med*, 2013, 369, s. 1327–1335.
- 9 Rosenstock, J.; CARMELINA Investigators: Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. *JAMA*, 2019, 321, s. 69–79.
- 10 Scirica, B. M.; SAVOR-TIMI 53 Steering Committee and Investigators: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*, 2013, 369, s. 1317–1326.
- 11 Williams, R. – de Vries, F. – Kothny, W., et al.: Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study. *Diabetes Obes Metab*, 2017, 19, s. 1473–1478.
- 12 Udeli, J. A. – Cavender, M. A. – Bhatt, D. L., et al.: Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol*, 2015, 3, s. 356–366.
- 13 Matthews, D. R., et al.; VERIFY study group: Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. *Lancet*, 2019, pii: S0140-6736(19)32131-2.
- 14 Goldstein, B. J.; Sitagliptin 036 Study Group: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care*, 2007, 30, s. 1979–1987.
- 15 Sinha, B. – Ghosal, S.: Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. *Diabetes Res Clin Pract*, 2019, 150, s. 8–16.
- 16 Tkáč, I. – Raz, I.: Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. *Diabetes Care*, 2017, 40, s. 284–286.
- 17 Kvapil, M. – Břízová, L. – Nováková, M.: Současné postavení gliptinů v léčbě diabetu. *Farmakoter Revue*, 2022, 7, s. 1–5.

# Biologická krytí v léčbě syndromu diabetické nohy

MUDr. Vladimíra Fejfarová, Ph.D. Diabetologické centrum, IKEM a 2. LF UK, Praha

MUDr. Veronika Wosková | MUDr. Michal Dubský Diabetologické centrum, IKEM, Praha

MUDr. Karol Sutoris, Ph.D. Klinika transplantáční chirurgie, transplantcentrum, IKEM, Praha

- 1 Dostupné z: <https://kdp.uzis.cz/res/guideline/27-syndrom-diabeticke-nohy-final.pdf>, vyhledáno 11. 2. 2022.
- 2 Fejfarová, V. – Jirkovská, A., et al.: *Léčba syndromu diabetické nohy odlehčením*. Maxdorf, 2015, s. 352.
- 3 Brem, H. – Tomic-Canic, M.: Cellular and molecular basis of wound healing in diabetes. *J Clin Invest*, 2007, 117, s. 1219–1222.
- 4 Uccioli, L. – Izzo, V. – Meloni, M., et al.: Non-healing foot ulcers in diabetic patients: general and local interfering conditions and management options with advanced wound dressings. *J Wound Care*, 2015, 24, s. 35–42.
- 5 Hu, S. C. – Lan, C. E.: High-glucose environment disturbs the physiological functions of keratinocytes: Focusing on diabetic wound healing. *J Dermatol Sci*, 2016, 84, s. 121–127.
- 6 Fejfarová, V. – Jirkovská, A. – Dubský, M., et al.: An alteration of lymphocytes subpopulations and immunoglobulins levels in patients with diabetic foot ulcers infected particularly by resistant pathogens. *J Diabetes Res*, 2016, 2016, s. 2356870.
- 7 Zhang, Z. – Zhang, W. – Xu, Y., et al.: Efficacy of hyperbaric oxygen therapy for diabetic foot ulcers: An updated systematic review and meta-analysis. *Asian J Surg*, 2022, 45, s. 68–78.
- 8 Thanigaimani, S. – Singh, T. – Golledge, J.: Topical oxygen therapy for diabetes-related foot ulcers: A systematic review and meta-analysis. *Diabet Med*, 2021, 38, s. e14585.
- 9 Moore, Z. E. – Corcoran, M. A. – Patton, D.: Nutritional interventions for treating foot ulcers in people with diabetes. *Cochrane Database Syst Rev*, 2020, 7, s. CD011378.
- 10 Li, X. – Xu, G. – Chen, J.: Tissue engineered skin for diabetic foot ulcers: a meta-analysis. *Int J Clin Exp Med*, 2015, 8, s. 18191–18196.
- 11 Pospíšilová, A.: Bioaktivní prostředky – nové trendy v místní terapii chronických ran. *Česká dermatovenerologie*, 2012, 2, s. 173–180.
- 12 Driver, V. R. – Lavery, L. A. – Reyzelman, A. M., et al.: A clinical trial of Integra Template for diabetic foot ulcer treatment. *Wound Repair Regen*, 2015, 23, s. 891–900.
- 13 Walters, J. – Cazzell, S. – Pham, H., et al.: Healing rates in a multicenter assessment of a sterile, room temperature, acellular dermal matrix versus conventional care wound management and an active comparator in the treatment of full-thickness diabetic foot ulcers. *Eplasty*, 2016, 6, e10.
- 14 Cazzell, S. – Vayser, D. – Pham, H., et al.: A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. *Wound Repair Regen*, 2017, 25, s. 483–497.
- 15 Caravaggi, C. – Grigoletto, F. – Scuderi, N.: Wound bed preparation with a dermal substitute (Hyalomatrix PA) facilitates re-epithelialization and healing: results of a multicenter, prospective, observational study on complex chronic ulcers (the FAST study). *Wounds*, 2011, 23, s. 228–235.
- 16 Dostupné z: <https://kdp.uzis.cz/index.php?pg=kdp&id=34>, vyhledáno 11. 2. 2022.
- 17 Lavery, L. A. – Fulmer, J. – Shebetka, K. A., et al.: The efficacy and safety of Grafix for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. *Int Wound J*, 2014, 11, s. 554–560.
- 18 Mohajeri-Tehrani, M. R. – Variji, Z. – Mohseni, S., et al.: Comparison of a bioimplant dressing with a wet dressing for the treatment of diabetic foot ulcers: a randomized, controlled clinical trial. *Wounds*, 2016, 28, s. 248–254.
- 19 Snyder, R. J. – Shimozaki, K. – Tallis, A., et al.: A prospective, randomized, multicenter, controlled evaluation of the use of dehydrated amniotic membrane Allograft compared to standard of care for the closure of chronic diabetic foot ulcer. *Wounds*, 2016, 28, s. 70–77.

# Využití moderních materiálů v lokální léčbě syndromu diabetické nohy – kazuistiky

MUDr. Robert Bém, Ph.D., MHA Centrum diabetologie, Institut klinické a experimentální medicíny, Praha

- 1 Boulton, A. J.: The diabetic foot: from art to science. The 18<sup>th</sup> Camillo Golgi lecture. *Diabetologia*, 2004, 47, s. 1343–1353.
- 2 Prompers, L. – Huijberts, M. – Apelqvist, J., et al.: High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. *Diabetologia*, 2007, 50, s. 18–25.
- 3 Hart, T. – Milner, R. – Cifu, A.: Management of a diabetic foot. *JAMA*, 2017, 318, s. 1387–1388.
- 4 Bem, R. – Dubský, M. – Fejfarová, V., et al.: Diabetic foot. *Vnitř Lek*, 2020, 66, s. 92–97.
- 5 Eleftheriadou, I. – Samakidou, G. – Tentolouris, A., et al.: Non-pharmacological management of diabetic foot ulcers: an update. *Int J Low Extrem Wounds*, 2021, 20, s. 188–197.
- 6 Jaffe, L. – Wu, S. C.: Dressings, topical therapy, and negative pressure wound therapy. *Clin Podiatr Med Surg*, 2019, 36, s. 397–411.
- 7 Keni, R. – Begum, F. – Gourishetti, K., et al.: Diabetic wound healing approaches: an update. *J Basic Clin Physiol Pharmacol*, 7. 1. 2022, doi: 10.1515/jbcpp-2021-0340.
- 8 Lustig, A. – Gefen, A.: Fluid management and strength postulated use of primary and secondary dressings for treating diabetic foot ulcers: Robotic phantom studies. *Int Wound J*, 2022, 19, s. 305–315.

# Co přinášejí nová doporučení pro léčbu srdečního selhání 2021 pro kardiology v první linii a praktické lékaře

prof. MUDr. Jiří Vítovec, CSc., FESC | prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC

I. interní kardiologická klinika LF MU a FN u svaté Anny v Brně

- 1 McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Europ Heart J*, 2021, 42, s. 3599–3726.

# Souhrn novinek z Doporučení pro diagnostiku a léčbu srdečního selhání Evropské kardiologické společnosti z roku 2021

prof. MUDr. Filip Málek, Ph.D., MBA Kardiovaskulární centrum Nemocnice Na Homolce, Praha

- 1 McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2021, 42, s. 3599–3726.
- 2 Hunt, S. A. – Baker, D. W. – Chin, M. H., et al.: M ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). *Circulation*, 2001, 104, s. 2996–3007.
- 3 Udelson, J. E. – Stevenson, L. W.: The future of heart failure diagnosis, therapy, and management. *Circulation*, 2016, 133, s. 2671–2686.

## Novinky v léčbě akutního srdečního selhání

prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC

I. interní kardiologická klinika FN u sv. Anny v Brně a LF MU, Brno

- 1 McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2021, 42, s. 3599–3726.
- 2 O'Connor, C. M. – Starling, R. C. – Hernandez, A. F., et al.: Effect of nesiritide in patients with acute decompensated heart failure. *N Engl J Med*, 2011, 365, s. 32–43.
- 3 Mitrovic, V. – Seferovic, P. M. – Simeunovic, D., et al.: Haemodynamic and clinical effects of ularitide in decompensated heart failure. *Eur Heart J*, 2006, 27, s. 2823–2832.
- 4 Packer, M. – O'Connor, C. – McMurray, J. J. V., et al.: Effect of ularitide on cardiovascular mortality in acute heart failure. *N Engl J Med*, 2017, 376, s. 1956–1964.
- 5 Metra, M. – Teerlink, J. R. – Cotter, G., et al.: Effects of serelaxin in patients with acute heart failure. *N Engl J Med*, 2019, 381, s. 716–726.
- 6 Felker, M. – McMurray, J. J. V. – Cleland, J. G., et al.: Effects of a novel nitroxyl donor in acute heart failure. The STAND-UP AHF Study. *JACC Heart Fail*, 2021, 9, s. 146–157.
- 7 Konstam, M. A. – Gheorghiade, M. – Burnett, J. C., et al.: Effects of oral tolvaptan in patients hospitalised for worsening heart failure. *JAMA*, 2007, 297, s. 1391–1331.
- 8 Metra, M. – O'Connor, C. M. – Davison, B. A., et al.: Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. *Eur Heart J*, 2011, 32, s. 1519–1534.
- 9 Teerlink, J. R. – Felker, M. – McMurray, J. J. V., et al.: Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: The ATOMIC-AHF study. *J Am Coll Cardiol*, 2016, 67, s. 1444–1455.
- 10 Greenberg, B. – Butler, J. – Felker, G. M., et al.: Calcium up regulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. *Lancet*, 2016, 387, s. 1178–1186.
- 11 Wachter, R. – Senni, M. – Belohlavek, J., et al.: Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSCITION trial. *Eur J Heart Fail*, 2019, 21, s. 998–1007.
- 12 Pascual-Figal, D. – Wachter, R. – Senni, M., et al.: NT-proBNP response to sacubitril/valsartan in hospitalised heart failure patients with reduced ejection fraction. *JACC Heart Failure*, 2020, 8, s. 822–833.
- 13 Velazquez, E. J. – Morrow, D. A. – DeVore, A. D., et al.: Angiotensin-neprilysin inhibition in acute decompensated heart failure. *N Engl J Med*, 2019, 380, s. 539–548.
- 14 Bhatt, D. L. – Szarek, M. – Steg, P. G., et al.: Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med*, 2021, 384, s. 117–128.
- 15 Voors, A. A. – Angermann, C. E. – Teerlink, J. R., et al.: Empagliflozin in patients hospitalised for acute heart failure: the EMPULSE trial. *AHA Congress*, 13–15. 11. 2021, Boston, USA.

## Vericiguat v léčbě srdečního selhání

prof. MUDr. Vojtěch Melenovský, CSc. Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

- 1 Armstrong, P. W. – Burkerd Pieske, B. – Anstrom, K. J., et al., on behalf of the VICTORIA Study Group: Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med*, 2020, 382, s. 1883–1893.
- 2 Butler, J. – Anstrom, K. J. – Armstrong, P. W.: Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA trial. *Circulation*, 2020, 142, s. 717–719.
- 3 Emdin, M. – Aimo, A. – Castiglione, V., et al.: Targeting cyclic guanosine monophosphate to treat heart failure. *J Am Coll Cardiol*, 2020, 76, s. 1795–1807.
- 4 Follmann, M. – Ackerstaff, J. – Redlich, G., et al.: Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. *J Med Chem*, 2017, 60, s. 5146–5161.
- 5 Kramer, F. – Voss, S. – Roessig, L., et al.: Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. *Eur J Heart Fail*, 2020, 22, s. 1675–1683.
- 6 Lam, C. S. P. – Mulder, H. – Lopatin, Y., et al.: VICTORIA Study Group: Blood pressure and safety events with vericiguat in the VICTORIA trial. *J Am Heart Assoc*, 2021, 10, s. e021094.
- 7 Ezekowitz, J. A. – O'Connor, C. M. – Troughton, R. W.: N-Terminal Pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. *JACC Heart Fail*, 2020, 8, s. 931–939.
- 8 Sandner, P. – Follmann, M. – Becker-Pelster, E., et al.: Soluble GC stimulators and activators: Past, present and future. *BJP*, 2021, doi.org/10.1111/bph.15698.
- 9 Gheorghiade, M. – Greene, S. J. – Butler, J.; SOCRATES-REDUCED Investigators and Coordinators: Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. *JAMA*, 2015, 314, s. 2251–2262.
- 10 McDonagh, T. A. – Metra, M. – Adamo, M.; ESC Scientific Document Group: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2021, 42, s. 3599–3726.

## Postavení spironolaktonu v terapii srdečního selhání

prof. MUDr. Filip Málek, Ph.D., MBA Kardiovaskulární centrum Nemocnice Na Homolce, Praha

- 1 Ponikowski, P. – Voors, A. A. – Anker, S. D., et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). *Eur Heart J*, 2016, 37, s. 2129–2200.
- 2 Špinar, J. – Hradec, J. – Špinarová, L. – Vitovec, J.: Souhrn Doporučených postupů ESC pro diagnostiku a léčbu akutního a chronického srdečního selhání z roku 2016. *Cor et Vasa*, 2016, 58, s. e530–e568.
- 3 McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2021, 42, s. 3599–3726.
- 4 Málek, F. – Špaček, R.: Blokáda receptoru aldosteronu v terapii chronického srdečního selhání. *Cor et Vasa*, 2002, 44, s. 32–36.
- 5 Pitt, B. – Zannad, F. – Remme, W. J., et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med*, 1999, 341, s. 709–717.
- 6 Duran, J. M. – Gad, S. – Brann, A., et al.: Mineralocorticoid receptor antagonist use following heart failure hospitalization. *ESC Heart Failure*, 2020, 7, s. 482–492.
- 7 Pitt, B. – Pfeffer, M. A. – Assman, S. F., et al.: for the TOPCAT Investigators: Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med*, 2014, 370, s. 1383–1392.

## SGLT2 a kardiovaskulární onemocnění v roce 2022

prof. MUDr. Jindřich Špinar, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC

I. interní kardiologická klinika FN u sv. Anny v Brně a LF MU, Brno

- 1 Ponikowski, P. – Voors, A. A. – Anker, S. D., et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*, 2016, 37, s. 2129–2200.
- 2 Seferovic, P. M. – Coats, A. J. S. – Ponikowski, P.: European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. *Eur J Heart Fail*, 2020, 22, s. 196–212.
- 3 Seferovic, P. M. – Ponikowski, P. – Anker, S. D., et al.: Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*, 2019, 21, s. 1169–1186.
- 4 Špinar, J. – Hradec, J. – Špinarová, L. – Vitovec, J.: Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of Cardiology. *Cor et Vasa*, 2016, 58, s. e530–e568.
- 5 Packer, M.: Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control. *Diabetes Obes Metab*, 2018, 20, s. 1766–1769.
- 6 Vitovec, J. – Špinar, J. – Špinarová, L.: Diabetes mellitus a kardiovaskulární onemocnění. *Kardiolog Revue Int Med*, 2018, 20, s. 118–125.
- 7 Špinar, J. – Špinarová, L. – Vitovec, J.: Srdeční selhání – novinky 2019. *Medicina – Kardiabetes*, 2019, s. 6–8.
- 8 Wanner, C. – Lachin, J. M. – Inzucchi, S. E., et al.: Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. *Circulation*,

- 2018, 137, s. 119–129.
- 9 **Zinman, B. – Wanner, C. H. – Lachin, J. M., et al.:** for the EMPA-REG OUTCOME Investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*, 2015, 373, s. 2117–2128.
- 10 **Verma, S. – Mazer, C. D. – Yan, A. T., et al.:** Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease. The EMPA-HEART CardioLink-6 clinical trial. *Circulation*, 2019, 140, s. 1693–1702.
- 11 **Špinar, J.:** Dapagliflozin a studie DECLARE – vstupní charakteristika. *Kardiolog Rev Int Med*, 2018, 20, s. 61–65.
- 12 **Wiviott, S. D. – Raz, M. – Bonaca, O., et al.:** Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2019, 380, s. 347–357.
- 13 **McMurray, J. J. V. – Solomon, S. D. – Inzucchi, S. E., et al.:** Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*, 2019, 381, s. 1995–2008.
- 14 **Špinar, J. – Špinarová, L. – Vítovec, J.:** EMPEROR-Reduced – empagliflozin u nemocných se srdečním selháním a nízkou ejekční frakcí. *Interv Akut Kardiolog*, 2020, 19, s. 238–241.
- 15 **Packer, M. – Anker, S. D. – Butler, J., et al.:** Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med*, 2020, 383, s. 1413–1424.
- 16 **Cannon, C. P. – Pratley, R. – Dagogo-Jack, S., et al.:** Cardiovascular outcomes with ertugliflozin in type 2 diabetes. *N Engl J Med*, 2020, 383, s. 1425–1435.
- 17 **Anker, S. D. – Butler, J. – Filipatos, J. P., et al.:** Empagliflozin and cardiovascular outcomes in heart failure with a preserved ejection fraction. *N Engl J Med*, 2021, 385, s. 1451–1461.
- 18 **McDonagh, T. A. – Metra, M. – Adamo, M., et al.:** 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2021, 42, s. 3599–3726.

## Klinické zkušenosti s moxonidinem v léčbě arteriální hypertenze – kazuistiky

MUDr. Jan Vachek Klinika nefrologie 1. LF UK a VFN, Praha, Interní oddělení a hemodialyzační středisko Klatovské nemocnice, a. s.

- 1 **Karlaftis, E. F. – Hatzitolios, A. I. – Karlaftis, A. F., et al.:** Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. *J Pharm Bioallied Sci*, 2013, 5, s. 253–256.
- 2 **Vachek, J.:** The use of moxonidine in the treatment of arterial hypertension. *Vnitřní Léč*, 2021, 67, s. 170–172. English. PMID: 34171957.
- 3 **Strauch, B. – Petrák, O. – Zelinka, T., et al.:** Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. *J Hypertens*, 2013, 31, s. 2455–2461.
- 4 **Edwards, L. P. – Brown-Bryan, T. A. – McLean, L., et al.:** Pharmacological properties of the central antihypertensive agent, moxonidine. *Cardiovasc Ther*, 2012, 30, s. 199–208.
- 5 **Talih, F. – Ghossoub, E.:** Moxonidine for tramadol withdrawal symptoms during detoxification. *Case Reports*, 2015, 2015:bcr2015210444.
- 6 **Vachek, J. – Maříková, A. – Oulehle, K. – Zakiyanov, O. – Tesař, V.:** Proteinuria from an internists point of view. *Vnitřní Léč*, 2020, 66, s. 90–92. English. PMID: 32972173.

## Měření krevního tlaku u pacientů s arytmiemi – v ambulanci i doma

MUDr. Petra Vysočanová Interní kardiologická klinika FN a LF MU, Brno

- 1 **Widimský, J. – Filipovský, J. – Ceral, J., et al.:** Diagnostické a léčebné postupy u arteriální hypertenze – verze 2017. Doporučení České společnosti pro hypertenzi. *Vnitřní Léč*, 2018; 64(7-8): 771–796.
- 2 **Williams, B. – Mancia, G. – Spiering, W., et al.:** 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *European Heart Journal*, 2018, 39, s. 3021–3104.
- 3 **Unger, T. – Borghi, C. – Chanchar, F., et al.:** 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension*, 2020, 75, s. 1334–1357.
- 4 **Stergiou, G. S. – Palatini, P. – Parati, G., et al.:** 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. *J Hypertens*, 2021, 39, s. 1293–1302.
- 5 **Stergiou, G. S. – Ntineri, A. – Kollias, A., et al.:** Changing relationship among clinic, home, and ambulatory blood pressure with increasing age. *J Am Soc Hypertens*, 2015, 9, s. 544–552.
- 6 **Stergiou, G. S. – Kyriakoulis, K. G. – Stambolliu, E., et al.:** Blood pressure measurement in atrial fibrillation: review and meta-analysis of evidence on accuracy and clinical relevance. *J Hypertens*, 2019, 37, s. 2430–2441.
- 7 **Kario, K. – Shimbo, D. – Hoshida, S., et al.:** Emergence of home blood pressure-guided management of hypertension based on global evidence. *Hypertension*, 2019, 74, HYPERTENSIONAHA11912630.
- 8 **Kario, K. – Hasebe, N. – Okumura, K., et al.:** High prevalence of masked uncontrolled morning hypertension in elderly non-valvular atrial fibrillation patients: Home blood pressure substudy of the ANAFIE Registry. *J Clin Hypertens*, 2021, 23, s. 73–82.
- 9 **Xie, F. – Xu, J. – Xia, L., et al.:** The impact of atrial fibrillation on accuracy of oscillometric blood pressure measurement: effect of ventricular rate. *Hypertens Res*, 2020, 43, s. 518–524.
- 10 **Xie, F. – Xu, J. – Liu, H., et al.:** Different impact factors for accurate oscillometric blood pressure measurement between sinus rhythm and atrial fibrillation. *J Hum Hypertens*, 2021, 35, s. 785–790.
- 11 **Clark, C. E. – McDonagh, S. T. J. – McManus, R. J.:** Accuracy of automated blood pressure measurements in the presence of atrial fibrillation: systematic review and meta-analysis. *J Hum Hypertens*, 2019, 33, s. 352–364.
- 12 **Balanis, T. – Sanner, B.:** Detection of atrial fibrillation using a home blood pressure monitor. *Vasc Health Risk Manag*, 2021, 17, s. 407–414.
- 13 **Pagonas, N. – Schmidt, S. – Eysel, J., et al.:** Impact of atrial fibrillation on the accuracy of oscillometric blood pressure monitoring. *Hypertension*, 2013, 62, s. 579–584, doi: 10.1161/HYPERTENSIONAHA.113.01426.

## Fibrilace síní – možnost řešení na jednotce intenzivní péče – kazuistika

Oleksii Stoiano | Eliška Klepšová anesteziologové, IKEM, Praha

- 1 **Maisel, W. H. – Rawns, J. D. – Stevenson, W. G.:** Atrial fibrillation after cardiac surgery. *Ann Intern Med*, 2001, 135, s. 1061–1073.
- 2 **Greenberg, J. W. – Lancaster, T. S. – Schuessler, R., et al.:** Post-operative atrial fibrillation following cardiac surgery: a persistent complication. *Eur J Cardiothorac Surg*, 2017, 52, s. 665–672.
- 3 **Hindricks, G. – Potpara, T. – Gagres, N., et al.:** 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*, 2021, 42, s. 373–498.

## Adherence pacientů s chronickým žilním onemocněním k doporučené léčbě

MUDr. Eva Jirešová Angiologická ambulance, Kardiocentrum Nemocnice Na Homolce, Praha

- 1 **Nicolaides, A. – Kakkos, S. – Baekgaard, N., et al.:** Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. *Int Angiol*, 2018, 37, s. 181–254.
- 2 **Kováčik, F. – Směkal, A. – Přeček, J., et al.:** Chronická žilní insuficience a varixy dolních končetin u mladých osob. *Kardiolog Rev Int Med*, 2018, 20, s. 109–111.
- 3 **Kankam, H. K. N. – Lim, C. S. – Fiorentino, F., et al.:** A summation analysis of compliance and complications of compression hosiery for patients with chronic venous disease or post-thrombotic syndrome. *Eur J Vasc Endovasc Surg*, 2018, 55, s. 406–416.
- 4 **Houtermans-Auckel, J. P. – van Rossum, E. – Teijink, J. A. W., et al.:** To wear or not to wear compression stockings after varicose vein stripping: a randomised controlled trial. *Eur J Vasc Endovasc Surg*, 2009, 38, s. 387–391.
- 5 **O'Hare, J. L. – Stephens, J. – Parkin, D., et al.:** Randomized clinical trial of different bandage regimens after foam sclerotherapy for varicose veins. *BJS*, 2010, 97, s. 650–656.
- 6 **Mušil, D.:** Chronické žilní onemocnění – podceňované i přeceňované, co nového? *Interní Med*, 2012, 14, s. 96–100.
- 7 **No authors listed. Update on Current Care Guideline: Venous insufficiency of the lower limb. Duodecim, 2017, 133, s. 571–572.**
- 8 **Karetová, D.:** *Optimální přístup k léčbě chronického žilního onemocnění.* Medical Tribune, 2021.
- 9 **Šlais, M. – Dvořáček, L. – Šedivý, P., et al.:** Radiofrekvenční ablace varixů dolních končetin pod ultrasonografickou kontrolou. *Rozhl Chir*, 2012, 91, s. 410–412.
- 10 **Černošská, J.:** Jak se žije s chronickým žilním onemocněním – příběhy pacientů v různých stadiích chronického žilního onemocnění. *Farmaterapeutická revue*, 2019.
- 11 **Zimolová, P.:** Podceňované chronické žilní onemocnění. *Causa subita*, 2018, 21, s. 86–88.